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Abstract
Introduction Ventilator-associated tracheobronchitis (VAT) is
associated with increased duration of mechanical ventilation.
We hypothesized that, in patients with VAT, antibiotic treatment
would be associated with reduced duration of mechanical
ventilation.
Methods We conducted a prospective, randomized, controlled,
unblinded, multicenter study. Patients were randomly assigned
(1:1) to receive or not receive intravenous antibiotics for 8 days.
Patients with ventilator-associated pneumonia (VAP) prior to
VAT and those with severe immunosuppression were not
eligible. The trial was stopped early because a planned interim
analysis found a significant difference in intensive care unit (ICU)
mortality.
Results Fifty-eight patients were randomly assigned. Patient
characteristics were similar in the antibiotic (n = 22) and no
antibiotic (n = 36) groups. Pseudomonas aeruginosa was
identified in 32% of VAT episodes. Although no difference was
found in mechanical ventilation duration and length of ICU stay,
mechanical ventilation-free days were significantly higher
(median [interquartile range], 12 [8 to 24] versus 2 [0 to 6] days,
P < 0.001) in the antibiotic group than in the no antibiotic group.
In addition, subsequent VAP (13% versus 47%, P = 0.011,
odds ratio [OR] 0.17, 95% confidence interval [CI] 0.04 to
0.70) and ICU mortality (18% versus 47%, P = 0.047, OR 0.24,
95% CI 0.07 to 0.88) rates were significantly lower in the
antibiotic group than in the no antibiotic group. Similar results
were found after exclusion of patients with do-not-resuscitate
orders and those randomly assigned to the no antibiotic group
but who received antibiotics for infections other than VAT or
subsequent VAP.
Conclusion In patients with VAT, antimicrobial treatment is
associated with a greater number of days free of mechanical
ventilation and lower rates of VAP and ICU mortality. However,
antibiotic treatment has no significant impact on total duration of
mechanical ventilation.
Trial registration ClinicalTrials.gov, number NCT00122057.
Introduction
Ventilator-associated tracheobronchitis (VAT) is common
among mechanically ventilated critically ill patients [1-3]. Pre-
vious studies found VAT to be associated with increased dura-
tion of mechanical ventilation and intensive care unit (ICU) stay
[1,4,5]. VAT is probably an intermediate process between
lower respiratory tract colonization and ventilator-associated
pneumonia (VAP). Postmortem studies showed a continuum
between bronchitis and pneumonia in mechanically ventilated
ICU patients [6].
ATS = American Thoracic Society; cfu = colony-forming units; COPD = chronic obstructive pulmonary disease; HRCT = high-resolution computed 
tomography; ICU = intensive care unit; ITT = intention-to-treat; MDR = multidrug-resistant; VAP = ventilator-associated pneumonia; VAT = ventilator-
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Few studies have evaluated the impact of antibiotic treatment
on the outcome of critically ill patients with VAT [1,4,5]. In a
prospective observational study [1], our group investigated
the impact of antibiotic treatment on the outcome of patients
with VAT. Among the 201 patients with VAT, 136 received
antibiotics. The mortality rate was significantly lower in VAT
patients who received antibiotics than in those who did not
receive antibiotics. However, after exclusion of VAT patients
who developed subsequent VAP, no significant difference
was found in mortality rate. A beneficial effect of antimicrobial
treatment on the duration of mechanical ventilation was also
suggested by an observational case-control study performed
in chronic obstructive pulmonary disease (COPD) patients
with VAT [4]. However, another case-control study performed
in VAT patients without chronic respiratory failure found no
impact of antimicrobial treatment on the duration of mechani-
cal ventilation [5]. Furthermore, it has been shown that sys-
temic antibiotics have no effect on the transition from VAT to
VAP [1].
Although no firm evidence on the beneficial effects of antibi-
otic treatment in patients with VAT exists, ICU physicians fre-
quently treat these patients with antibiotics [7-10]. However,
excessive usage of antibiotics in the ICU is associated with the
subsequent emergence of multidrug-resistant (MDR) bacteria
and worse outcome [11-14]. In their recent guidelines [15],
the American Thoracic Society (ATS) and the Infectious Dis-
ease Society of America recommended the performance of
randomized studies to determine whether patients with VAT
should be treated with antibiotics. Therefore, we conducted
this prospective, randomized, controlled, multicenter study to
determine the impact of antimicrobial treatment on outcome in
VAT patients.
Materials and methods
The study was conducted in 12 ICUs in the north of France
from June 2005 to June 2007. The study protocol was
approved by the institutional review board on human research
of the Lille university hospital. All patients or their next of kin
gave written informed consent before enrolment in the study.
The eligibility criteria for the study were age older than 18
years and the presence of a first episode of VAT diagnosed
more than 48 hours after starting mechanical ventilation.
Before random assignment, patients were excluded if they (a)
were pregnant, (b) had a history of severe immunosuppres-
sion, (c) had a tracheostomy at ICU admission (however,
patients were eligible if they had a tracheostomy performed
after ICU admission), (d) had a VAP before VAT, (e) had
already participated in this study, (f) were already included in
another trial, or (g) had little chance of survival as defined by a
Simplified Acute Physiology Score (SAPS II) of greater than
65 points.
Random assignment and antibiotic treatment
Patients were randomly assigned to receive or not receive
intravenous antimicrobial treatment for 8 days. The duration of
antimicrobial treatment was based on the results of a large
multicenter randomized study on the duration of antibiotic ther-
apy in patients with VAP [16]. A computer-generated random
assignment list in balanced blocks of four was assigned to
each participating ICU. Treatment assignments were con-
tained in sealed opaque individual envelopes that were num-
bered sequentially.
The study was not blinded. The initial empirical antibiotic regi-
men was based on results of the last endotracheal aspirate
culture. In the antibiotic group, the initial antibiotic treatment
was modified, if inappropriate, after receipt of definitive micro-
biologic results identifying the pathogen(s) and its susceptibil-
ity patterns. In the no antibiotic group, antibiotics could be
given for subsequent VAP or infections other than VAT or sub-
sequent VAP.
Study population
In all patients, quantitative endotracheal aspirate was per-
formed at ICU admission and weekly thereafter. In addition,
quantitative endotracheal aspirate was performed in patients
with suspicion of VAT or VAP. Moreover, quantitative endotra-
cheal aspirate was performed in all included patients at the
day of random assignment (before starting antibiotics in the
antibiotic group) and day 8 after random assignment if patients
were still intubated. Microbiological data were available to phy-
sicians in different centers. Routine screening of MDR bacte-
ria was performed in study patients at random assignment and
weekly thereafter. This screening included nasal and anal
swabs. Other microbiologic cultures were performed accord-
ing to clinical status. In all participating ICUs, weaning from
mechanical ventilation was performed according to recom-
mendations of the French Society of Critical Care [17]. The
ventilator circuit was not changed routinely. Patients were kept
in a semirecumbent position during most of the period of
mechanical ventilation. Subglottic secretion drainage and
closed tracheal suction devices were not used. No patient
received aerosolized antibiotics. All patients were followed
until ICU discharge or 28 days after random assignment if they
were discharged from the ICU before.
Definitions
VAT was defined using all of the following criteria [1]: fever
(>38°C) with no other recognizable cause, purulent sputum
production, positive (≥106 colony-forming units [cfu] per millili-
ter) endotracheal aspirate culture [18] yielding a new bacteria
(not present at intubation), and no radiographic signs of new
pneumonia. All of these criteria had to be present before ran-
dom assignment. The absence of radiographic signs of new
pneumonia was based on physician staff decision in different
centers. Only first episodes of VAT occurring more than 48
hours after starting mechanical ventilation were taken intoAvailable online http://ccforum.com/content/12/3/R62
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account. VAP was defined by the presence of new or progres-
sive radiographic infiltrate associated with two of the following
criteria: (a) temperature of greater than 38.5°C or less than
36.5°C, (b) leukocyte count of greater than 10,000/μL or less
than 1,500/μL, and (c) purulent endotracheal aspirate and
positive (≥ 106 cfu/mL) endotracheal aspirate. VAP episodes
occurring less than 5 days after starting mechanical ventilation
were considered as early-onset. Late-onset VAP was defined
as VAP diagnosed at least 5 days after starting mechanical
ventilation. Other definitions of nosocomial infections were
based on criteria of the Centers for Disease Control and Pre-
vention [19]. Colonization was defined as a positive microbio-
logic culture without clinical signs of infection. Infection and
colonization were considered as ICU-acquired if they were
diagnosed more than 48 hours after ICU admission. MDR bac-
teria were defined as methicillin-resistant Staphylococcus
aureus, ceftazidime- or imipenem-resistant Pseudomonas aer-
uginosa,  Acinetobacter baumannii, extending-spectrum β-
lactamase-producing Gram-negative bacilli, and Stenotropho-
monas maltophilia.
Prior antibiotic treatment was defined as any antibiotic treat-
ment during the two weeks preceding ICU admission. In the
antibiotic group, antimicrobial therapy was considered appro-
priate when at least one antibiotic active in vitro on all organ-
isms causing VAT was administrated to treat VAT. De-
escalation was defined as changing the focus from multiple
agents to a single agent if P. aeruginosa was not present or as
changing from a broad to a narrow agent based on culture
data [20]. Severe immunosuppression was defined by the
presence of neutropenia (leucocyte count of less than 1,000/
μL or neutrophil count of less than 500/μL), active solid or
hematology malignancy, long-term corticosteroid therapy (≥1
mg/kg per day for more than 1 month), or HIV infection (CD4
of less than 50/μL during the previous 6 months). COPD was
defined according to recent ATS/European Respiratory Soci-
ety criteria [21]. Impossible-to-wean patients were defined as
those patients transferred from the ICU under mechanical ven-
tilation through a tracheostomy tube. The number of mechani-
cal ventilation-free days at 28 days after random assignment
was calculated [22]. For example, a patient who survived 28
days and received mechanical ventilation for 10 days was
assigned a value of 18. If mechanical ventilation had been
used for 10 days and the patient died on day 14, a value of 4
was assigned. The primary endpoint was duration of mechan-
ical ventilation. Secondary endpoints included mechanical
ventilation-free days, length of ICU stay, subsequent VAP, ICU
mortality, and infection or colonization related to MDR
bacteria.
Statistical methods
SPSS software (SPSS Inc., Chicago, IL, USA) was used for
data analysis. Qualitative variables were compared using the
chi-square test or the Fisher exact test where appropriate. The
distribution of continuous variables was tested. The Student t
test and the Mann-Whitney U test were used to compare con-
tinuous variables normally and abnormally distributed, respec-
tively. Results are presented as number (percentage) for
frequencies. The results of continuous variables are presented
as mean ± standard deviation if normally distributed or as
median (interquartile range) for abnormally distributed varia-
bles. Odds ratios and 95% confidence intervals were calcu-
lated for all significant (P < 0.05) qualitative variables. All P
values were two-tailed. The time to occurrence of ICU death
was analyzed in the antibiotic and no antibiotic groups by Kap-
lan-Meier survival curves.
All analyses were performed on an intention-to-treat (ITT)
basis. In addition, a modified ITT analysis was performed after
exclusion of (a) patients randomly assigned to the no antibiotic
group but who received (for infections other than VAT or sub-
sequent VAP) an antibiotic active in vitro on microorganisms
responsible for VAT, (b) impossible-to-wean patients, and (c)
patients with do-not-resuscitate orders. The aim of this modi-
fied ITT analysis was to adjust for these potential confounders.
Based on our previous study [1], it was expected that the dura-
tion of mechanical ventilation would be 22 ± 15 days in
patients with VAT. The inclusion of 350 patients (175 in each
group) was required to detect a difference in mechanical ven-
tilation duration of 5 days between the antibiotic and no anti-
biotic groups (two-sided α = 0.025, power = 0.90). An interim
analysis was planned at the inclusion of 175 patients or 2
years after starting the study if the number of included patients
was less than 175.
Results
Sixty-five patients were eligible for this study. Seven patients
refused to participate. Fifty-eight patients were randomly
assigned, including 22 patients in the antibiotic group and 36
patients in the no antibiotic group. Fourteen patients were
excluded from the modified ITT analysis (4 of 22 [18%] versus
10 of 36 [27%], P = 0.533, in the antibiotic and no antibiotic
groups, respectively). Among the 14 excluded patients, 8
patients were excluded for do-not-resuscitate orders (4 of 22
[18%] versus 4 of 36 [11%], P = 0.462) and 6 patients were
excluded because they were randomly assigned to the no anti-
biotic group but received antibiotics for infections other than
VAT or subsequent VAP (5 bacteremia and 1 severe sepsis)
during the 8 days following random assignment. No patient
was excluded for impossible weaning from mechanical ventila-
tion (Figure 1).
The planned interim analysis was performed 2 years after start-
ing the study because the number of included patients was
less than 175. The study was stopped by the local institutional
review board and safety committee because the interim analy-
sis found a significant difference in ICU mortality.Critical Care    Vol 12 No 3    Nseir et al.
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Patient characteristics were similar at ICU admission and at
the day of random assignment (Tables 1 and 2). Patients with
community-acquired pneumonia at ICU admission had all
completed antibiotic treatment for community-acquired pneu-
monia before inclusion in the study.
Microbiologic results and antimicrobial treatment
P. aeruginosa was the most frequently isolated bacteria in VAT
patients (32%). The rate of fluoroquinolone-resistant P. aeru-
ginosa was similar in the two groups (6 of 8 [75%] versus 8 of
11 [72%], P  = 0.689, in the antibiotic and no antibiotic
groups, respectively). The microorganisms isolated at a signif-
icant threshold are presented in Table 3. In the no antibiotic
group, two patients had additional microorganisms cultured at
less than 106 cfu/mL (P. aeruginosa and methicillin-sensitive
S. aureus). The bacteria identified on quantitative endotra-
cheal aspirate at random assignment were the same as those
identified on previous endotracheal aspirate in 48 of 58 (82%)
patients (17 of 22 [77%] versus 31 of 36 [86%], P = 0.481,
in the antibiotic and no antibiotic groups, respectively). The
number of patients with different concentrations of microor-
ganisms at different endpoints is presented in Figures 2 and 3.
In the antibiotic group, 16 of 22 (72%) patients received com-
bination therapy and 6 (27%) patients received monotherapy.
Aminoglycosides (45%) and imipenem (40%) were the most
frequently prescribed antibiotics (Table 4). In the antibiotic
group, 21 of 22 (95%) patients received appropriate initial
antibiotic treatment. In the patient who received inappropriate
initial treatment, antimicrobial therapy was modified after
receipt of identification of causal bacteria (48 hours after
random assignment). De-escalation was performed in 4 of 22
(18%) patients.
Ventilator-associated pneumonia patients
Twenty of 58 (34%) patients developed subsequent VAP. All
VAP episodes were late-onset. Twenty-six microorganisms
were identified at a significant threshold in patients with VAP.
P. aeruginosa was the most frequently isolated bacteria
(51%). The rate of VAP episodes related to the same microor-
ganism identified as a causative agent for VAT was signifi-
cantly lower in the antibiotic group than in the no antibiotic
group (0 of 3 [0%] versus 14 of 17 [82%], P = 0.018, respec-
tively). No significant difference was found in the duration of
mechanical ventilation between random assignment and VAP
occurrence (9 ± 6 versus 6.2 ± 4 days, P = 0.262, in the anti-
biotic and no antibiotic groups, respectively). In the control
group, no significant difference was found in procalcitonin
level at random assignment between patients with subsequent
VAP and patients without subsequent VAP (median 0.8 [inter-
quartile range 0.5 to 2.8] versus 0.75 [0.45 to 2.5] ng/mL, P
= 0.568). Other patient characteristics were also similar in
these two subgroups at ICU admission and at random assign-
ment (data not shown).
Patient characteristics during the intensive care unit stay
Patient characteristics during the ICU stay were similar in the
two groups (Table 5). At day 8 after random assignment, the
rate of positive endotracheal aspirate was significantly lower in
the antibiotic group than in the no antibiotic group (2 of 17
[11%] versus 21 of 26 [80%], P < 0.001, respectively).
Outcomes
Although the duration of mechanical ventilation and length of
ICU stay were similar in the two groups, mechanical ventila-
tion-free days were significantly higher in patients who
received antibiotics than in those who did not receive antibiot-
ics. In addition, subsequent VAP and ICU mortality rates were
significantly lower in the antibiotic group than in the no antibi-
otic group. Kaplan-Meier survival curves are presented in Fig-
ure 4. Reasons for death included life support withdrawal in 8
patients (4 of 22 [18%] versus 4 of 36 [11%], P = 0.462) and
multiple organ failure in 13 patients (0 of 22 versus 13 of 36
[36%], P < 0.001, in the antibiotic and no antibiotic groups,
respectively). No significant difference was found in the rates
of infection or colonization related to MDR bacteria diagnosed
after random assignment (Table 6). No significant difference
was found in outcome between different study centers (data
Figure 1
Profile of modified intention-to-treat analysis Profile of modified intention-to-treat analysis. DNR, do not resuscitate.Available online http://ccforum.com/content/12/3/R62
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not shown). No Clostridium difficile colitis was diagnosed in
study patients.
Discussion
The main results of our study are the following: (a) In patients
with VAT, antibiotic treatment was associated with signifi-
cantly lower ICU mortality and subsequent VAP rates and
more mechanical ventilation-free days. (b) No significant differ-
ence was found in the rate of infection or colonization related
to MDR bacteria diagnosed after random assignment between
the two groups. (c) No significant difference was found in the
Table 1
Patient characteristics at intensive care unit admission
Intention to treat Modified intention to treat
Antibiotic treatment
n = 22
No antibiotic treatment
n = 36
P value Antibiotic treatment
n = 18
No antibiotic treatment
n = 26
P value
Age, years 62 ± 15 67 ± 12 0.194 61 ± 15 67 ± 12 0.321
Male gender 15 (68) 24 (66) >0.999 13 (72) 16 (61) 0.531
SAPS II 47 ± 14 47 ± 18 0.994 45 ± 17 48 ± 15 0.481
LOD score 6.6 ± 3.5 6.2 ± 3.6 0.711 6.5 ± 3.8 6.4 ± 3.9 0.990
McCabe 0.687 0.625
Nonfatal underlying disease 10 (45) 14 (38) 10 (55) 11 (42)
Ultimately fatal underlying 
disease
9 (40) 17 (47) 7 (38) 12 (46)
Rapidly fatal underlying 
disease
3 (13) 5 (13) 1 (5) 3 (11)
Admission category >0.999 0.409
Medical 19 (86) 30 (83) 15 (83) 21 (80)
Surgical 3 (13) 5 (13) 3 (16) 4 (15)
Trauma 0 (0) 1 (2) 0 (0) 1 (3)
Comorbidities
COPD 9 (40) 17 (47) 0.787 7 (38) 12 (46) 0.760
Cardiac failure 6 (27) 4 (11) 0.156 6 (33) 3 (11) 0.128
Cirrhosis 0 (0) 3 (8) 0.281 0 (0) 3 (11) 0.258
Chronic dialysis 4 (18) 2 (5) 0.187 3 (16) 1 (3) 0.289
Diabetes mellitus 6 (27) 3 (8) 0.070 5 (27) 3 (11) 0.204
Transfer from other wards 12 (54) 12 (33) 0.285 9 (50) 9 (34) 0.361
Prior antibiotic treatment 9 (40) 12 (33) 0.585 8 (44) 8 (30) 0.525
Infection at ICU admission 18 (81) 25 (69) 0.365 14 (77) 20 (76) >0.999
Cause for ICU admission
Community-acquired 
pneumonia
6 (27) 10 (27) >0.999 6 (33) 6 (23) 0.506
Acute exacerbation of 
COPD
3 (13) 14 (38) 0.073 3 (16) 9 (34) 0.303
Congestive heart failure 3 (13) 1 (2) 0.319 3 (16) 1 (3) 0.289
Neurologic failure 2 (9) 5 (13) 0.698 1 (5) 4 (15) 0.634
Acute poisoning 2 (9) 2 (5) 0.681 2 (11) 2 (7) >0.999
Others 6 (27) 4 (11) 0.156 3 (16) 4 (15) >0.999
Results of univariate analysis are presented. Data are expressed as frequency (percentage) or mean ± standard deviation. COPD, chronic 
obstructive pulmonary disease; ICU, intensive care unit; LOD, logistic organ dysfunction; SAPS, Simplified Acute Physiology Score.Critical Care    Vol 12 No 3    Nseir et al.
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total duration of mechanical ventilation or ICU stay between
the antibiotic and no antibiotic groups.
To our knowledge, this is the first randomized study aiming at
evaluating the impact of antibiotic treatment on the outcome of
patients with VAT. The beneficial effect of antibiotics found in
this study on the number of days free of mechanical ventilation
could be explained by the reduction of secretion volume and
tracheobronchial inflammation. Palmer and colleagues [23,24]
investigated the impact of aerosolized antibiotics on secretion
Table 2
Patient characteristics at the day of random assignment
Intention to treat Modified intention to treat
Antibiotic treatment
n = 22
No antibiotic treatment
n = 36
P value Antibiotic treatment
n = 18
No antibiotic treatment
n = 26
P value
Duration of mechanical ventilation 
before random assignment, days
17 ± 9 13 ± 6 0.232 17 ± 10 12 ± 6 0.113
SAPS II 33 ± 13 36 ± 13 0.195 32 ± 10 36 ± 12 0.120
LOD score 4.1 ± 2 4.9 ± 2.4 0.185 3.8 ± 1.5 4.8 ± 2.6 0.210
Temperature, °C 38.1 ± 0.6 38.3 ± 0.6 0.408 38.2 ± 0.5 38.2 ± 0.4 0.402
Leucocytes, × 109 cells/L 12 ± 5.9 12 ± 6 0.619 11.2 ± 4.2 11.9 ± 5.7 0.775
C-reactive protein, mg/mL 111 ± 61 104 ± 80 0.417 104 ± 50 95 ± 67 0.295
Procalcitonin, ng/mL, median (IR) 0.6 (0.10–3.1) 0.8 (0.5–2.7) 0.282 0.7 (0.05–2.8) 0.83 (0.36–2.1) 0.494
Results of univariate analysis are presented. Data are expressed as mean ± standard deviation unless otherwise indicated. IR, interquartile range; LOD, logistic organ 
dysfunction; SAPS, Simplified Acute Physiology Sc
Table 3
Bacteria associated with ventilator-associated tracheobronchitis episodes
Intention to treat Modified intention to treat
Antibiotic treatment
n = 22
No antibiotic treatment
n = 36
Antibiotic treatment
n = 18
No antibiotic treatment
n = 26
Microorganisms, number 27 39 22 29
Polymicrobial VAT 5 (22) 3 (8) 4 (22) 3 (11)
MDR bacteria 10 (45) 17 (47) 9 (50) 14 (53)
Gram-negative 20 (90) 27 (75) 16 (88) 20 (76)
Pseudomonas aeruginosa 8 (36) 11 (30) 7 (31) 9 (34)
Enterobacter species 2 (9) 3 (8) 2 (11) 3 (11)
Escherichia coli 3 (13) 3 (8) 1 (5) 2 (7)
Proteus mirabilis 3 (13) 1 (2) 2 (11) 1 (3)
Citrobacter freundii 1 (4) 2 (5) 1 (5) 1 (3)
Acinetobacter baumannii 0 (0) 2 (5) 0 (0) 2 (7)
Morganella morgani 1 (4) 2 (5) 1 (5) 1 (3)
Hemophilus influenzae 0 (0) 1 (2) 0 (0) 1 (3)
Stenotrophomonas maltophilia 1 (4) 1 (2) 1 (5) 0 (0)
Klebsiella oxytoca 1 (4) 1 (2) 1 (5) 0 (0)
Gram-positive 7 (31) 12 (33) 6 (33) 9 (34)
Methicillin-resistant Staphylococcus aureus 3 (13) 6 (16) 3 (16) 5 (19)
Methicillin-sensitive S. aureus 3 (13) 4 (11) 2 (11) 4 (15)
Streptococcus pneumoniae 1 (4) 2 (5) 1 (5) 0 (0)
P > 0.2 for all comparisons (antibiotic versus no antibiotic treatment). Results are presented as number (percentage) unless otherwise indicated. MDR, multidrug-
resistant; VAT, ventilator-associated tracheobronchitis.Available online http://ccforum.com/content/12/3/R62
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volume in chronically mechanically ventilated patients with
VAT. In those studies, aerosolized antibiotics eradicated respi-
ratory pathogens, decreased inflammatory cells and the vol-
ume of secretions, and were not associated with increased
resistance. Increased secretion volume is a well-known risk
factor for difficult weaning from mechanical ventilation [25].
However, these factors were not evaluated in our study. The
absence of a significant difference in the total duration of
mechanical ventilation is probably related to the small number
of patients included in the study as compared with the number
of patients required to demonstrate a significant difference.
However, the number of days free of mechanical ventilation
explained by the fact that the mortality rate was significantly
higher in patients in the no antibiotic group and by the longer
duration of mechanical ventilation before random assignment
in the antibiotic group.
Lower rates of VAP and ICU mortality were found in VAT
patients who received antimicrobial treatment. Similar results
were found in a recent randomized study conducted in COPD
patients mechanically ventilated for severe acute exacerbation
[26]. However, in that study, all included patients had commu-
nity-acquired bronchitis. In addition, no bacteria could be
found in 38% of included patients. Although the severity of ill-
ness and predicted mortality were similar in the two groups,
mortality rate was significantly higher in the control group. This
result is probably related not to VAT but to the higher rate of
VAP in control patients. In addition, all VAP episodes were
late-onset and the rate of P. aeruginosa VAP was high. Previ-
ous studies demonstrated that VAP was associated with
increased mortality rate [27,28]. A recent study found higher
mortality rates in patients with late-onset VAP as compared
with patients with early-onset VAP [28]. P. aeruginosa VAP
was also found to be associated with high mortality rates [29].
Figure 2
Number of patients randomly assigned to the antibiotic group with dif- ferent concentrations of microorganisms in the endotracheal aspirate at  different time points Number of patients randomly assigned to the antibiotic group with dif-
ferent concentrations of microorganisms in the endotracheal aspirate at 
different time points. Five patients had polymicrobial ventilator-associ-
ated tracheobronchitis (VAT).
Figure 3
Number of patients randomly assigned to the control group with differ- ent concentrations of microorganisms in the endotracheal aspirate at  different time points Number of patients randomly assigned to the control group with differ-
ent concentrations of microorganisms in the endotracheal aspirate at 
different time points. Two patients had polymicrobial ventilator-associ-
ated tracheobronchitis (VAT).
Table 4
Antibiotics prescribed for ventilator-associated 
tracheobronchitis episodes
n = 22
Aminoglycosides 10 (45)
Imipenem 9 (40)
Ciprofloxacin 5 (22)
Piperacillin/tazobactam 5 (22)
Ceftazidime 1 (4)
Ticarcillin/clavulanate 1 (4)
Amoxicillin/clavulanate 1 (4)
Methicillin 1 (4)
Ceftriaxone 1 (4)
Vancomycin 1 (4)
Rifampin 1 (4)
Colimycin 1 (4)
Tigecycline 1 (4)
Combination therapy 16 (72)
β-lactams and aminoglycosides 9 (40)
β-lactams and ciprofloxacin 5 (22)
Vancomycin and aminoglycoside 1 (4)
Colimycin and rifampin 1 (4)
Results are presented as number (percentage). Monotherapy was 
given to patients with ventilator-associated tracheobronchitis related 
to methicillin-sensitive Staphylococcus aureus (n = 2), Escherichia 
coli (n = 2), Streptococcus pneumoniae (n = 1), and methicillin-
resistant S. aureus (n = 1).Critical Care    Vol 12 No 3    Nseir et al.
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However, other studies suggested that VAP was not associ-
ated with an increased mortality rate [30,31]. Another poten-
tial explanation for the higher mortality rate in untreated
patients is the possible presence of pneumonia in these
patients. VAT may be difficult to differentiate from VAP
because of the low sensitivity of chest portable radiographs in
ICU patients [32,33]. Though not statistically significant, the
duration of mechanical ventilation from random assignment to
VAP occurrence was shorter in the no antibiotic group than in
the antibiotic group. This result suggests that VAP might have
been present at the time of random assignment despite the
absence of new infiltrate on the chest radiograph. In a pro-
spective, observational, multicenter, cohort study performed
on 2,706 patients, outcomes of patients with suspected pneu-
monia and normal chest radiographs (33%) have been pro-
spectively investigated [34]. Similar rates of positive sputum
cultures, positive blood cultures, and mortality were found in
patients without radiographic pneumonia as compared with
patients with radiographic pneumonia. In a recent study [35],
accuracy of chest radiography was compared with high-reso-
lution computed tomography (HRCT) in 47 patients with sus-
pected community-acquired pneumonia. HRCT identified all
18 community-acquired pneumonia cases (38%) apparent on
radiographs as well as 8 additional cases (17%). The
performance of HRCT could be suggested to better diagnose
VAP in critically ill patients. However, recent guidelines require
the presence of new infiltrate on a chest radiograph as a crite-
rion for VAP diagnosis [15]. Therefore, a baseline examination
should be available for all patients to diagnose a new infiltrate
on HRCT. Such a strategy would be expensive and difficult to
apply in critically ill patients. The absence of new infiltrate on a
chest radiograph could be more difficult to diagnose in
patients with an abnormal chest radiograph at ICU admission.
In our study, 38% of study patients had an abnormal chest
radiograph at ICU admission. However, patients admitted to
the ICU frequently have an abnormal chest radiograph [36].
The rate of COPD (44%) was high. However, no significant
difference was found in COPD rate between the two groups.
A previous observational study identified COPD as a risk fac-
tor for VAT [1]. The rate of patients with multiple organ failure
was significantly higher in the control group than in the antibi-
Table 5
Patient characteristics during the intensive care unit stay
Intention to treat Modified intention to treat
Antibiotic treatment
n = 22
No antibiotic treatment
n = 36
P value Antibiotic treatment
n = 18
No antibiotic treatment
n = 26
P value
Tracheostomy 5 (22) 5 (13) >0.999 5 (27) 5 (19) 0.716
Corticosteroid use 8 (36) 19 (52) 0.283 6 (33) 13 (50) 0.359
Septic shock 1 (4) 7 (19) 0.134 1 (5) 5 (19) 0.375
ICU-acquired infections other 
than VAT and VAPa
7 (31) 18 (50) 0.274 6 (33) 13 (50) 0.359
Bacteremia 6 (27) 13 (36) 0.572 5 (27) 8 (30) >0.999
Urinary tract infection 2 (9) 5 (13) 0.698 2 (11) 5 (19) 0.682
Others 2 (9) 2 (5) >0.999 2 (11) 2 (7) >0.999
Total duration of antibiotic 
treatment, days
25 ± 14 19 ± 15 0.149 24 ± 15 17 ± 15 0.104
Antibiotic treatment before 
VAT
18 (81) 29 (80) >0.999 15 (83) 23 (88) 0.676
Antibiotic treatment during the 
8 days following random 
assignment
22 (100) 21 (58) <0.001 18 (100) 10 (38) <0.001
Reasons for antibiotic 
treatment during the 8 days 
following random assignment
VAT 22 (100) 0 (0) <0.001 18 (100) 0 (0) <0.001
VAP 0 (0) 15 (41) <0.001 0 (0) 10 (38) 0.003
Other infections 0 (0) 6 (16) 0.073 0 (0) 0 (0) NA
Antibiotic treatment after day 8 
post-random assignment
6 (27) 8 (22) 0.756 3 (16) 5 (19) >0.999
Results of univariate analysis are presented. Data are expressed as frequency (percentage) or mean ± standard deviation. aSome patients had 
more than one ICU-acquired infection. ICU, intensive care unit; NA, not applicable; VAP, ventilator-associated pneumonia; VAT, ventilator-
associated tracheobronchitis.Available online http://ccforum.com/content/12/3/R62
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otic group. This result could be explained by the higher rate of
VAP in these patients. Previous studies found VAP to be asso-
ciated with multiple organ failure [37,38].
VAT could also be difficult to differentiate from lower respira-
tory tract colonization. Several factors support the presence of
infection rather than colonization in our patients: (a) Quantita-
tive endotracheal aspirate was used with a high threshold (106
cfu/mL) to diagnose VAT, (b) only new bacteria were taken
into account, (c) all patients had fever, and (d) leucocyte, C-
reactive protein, and procalcitonin levels were high in study
patients. Although fever and high leucocyte and C-reactive
protein levels may simply reflect the presence of systemic
inflammatory response, procalcitonin is useful in differentiating
bacterial sepsis from systemic inflammatory response in criti-
cally ill patients [39-41]. However, the exclusion of pathogens
present at the time of intubation could be a matter of debate
since these pathogens could be responsible for VAT. In addi-
tion, microorganisms cultured at a lower concentration (<106
cfu/mL) might be associated with VAT [2]. On the other hand,
one could argue that patients with a high microorganism count
on tracheal aspirate cultures and no radiographic infiltrates
should be treated with antibiotics. However, stable patients
receiving prolonged mechanical ventilation without clinical
pneumonia have a high alveolar burden of bacteria [42]. There-
fore, the presence of purulent tracheal aspirate and fever is
important to determine patients who would benefit from anti-
microbial treatment.
This study has some limitations. First, the trial stopped early
after the planned interim analysis showed a significant reduc-
tion of ICU mortality rate in the antibiotic group. Therefore, sev-
eral random assignment blocks could not be ended, resulting
in an imbalance in the numbers of patients randomly assigned
to the antibiotic or control group. One could argue that no sig-
nificant difference was found in the primary endpoint. How-
ever, the significant difference in ICU mortality, subsequent
VAP, and mechanical ventilation-free days represents over-
whelming evidence of benefit to justify stopping the trial early.
In addition, this endpoint was no longer relevant given the dif-
ference in ICU mortality. Second, the study was not blinded
and antibiotic treatment was not standardized in all treated
patients. However, blinding was not possible using a targeted
antibiotic strategy based on results of previous endotracheal
aspirate culture. The aim of such a strategy was to reduce the
usage of broad-spectrum antibiotics and to provide a higher
rate of appropriate initial antibiotic treatment. A recent study
found routine surveillance endotracheal aspirate useful to pre-
Table 6
Outcomes of study patients
Intention to treat Modified intention to treat
Antibiotic treatment
n = 22
No antibiotic treatment
n = 36
P value Antibiotic treatment
n = 18
No antibiotic treatment
n = 26
P value
Duration of mechanical 
ventilation, days
29 ± 17 26 ± 15 0.816 26 ± 15 24 ± 15 0.952
Mechanical ventilation-free 
days, median (interquartile 
range)
12 (8–24) 2 (0–6) <0.001 16 (9–25) 4 (2–10) 0.001
Length of ICU stay, days 40 ± 23 36 ± 21 0.558 37 ± 21 33 ± 20 0.445
Ventilator-associated 
pneumonia
3 (13) 17 (47) 0.011a 2 (11) 12 (46) 0.021a
ICU mortalityb 4 (18) 17 (47) 0.047a 0 (0) 11 (42) 0.001a
Infection or colonization 
related to MDR bacteria
9 (40) 13 (36) 0.784 7 (38) 8 (30) 0.748
Ceftazidime or imipenem-
resistant Pseudomonas 
aeruginosa
3 (13) 6 (16) 0.534 3 (16) 5 (19) >0.999
Acinetobacter baumannii 0 (0) 2 (5) 0.521 0 (0) 0 (0) NA
Stenotrophomonas 
maltophilia
1 (4) 0 (0) 0.379 1 (5) 0 (0) 0.409
Methicillin-resistant 
Staphylococcus aureus
2 (9) 1 (2) 0.551 1 (5) 0 (0) 0.409
ESBL-producing Gram-
negative bacilli
3 (13) 4 (11) 0.540 2 (11) 3 (11) >0.999
Results of univariate analysis are presented. Data are expressed as frequency (percentage) or mean ± standard deviation unless otherwise 
indicated. aOdds ratios (95% confidence intervals) are 0.17 (0.04 to 0.70), 0.14 (0.02 to 0.76), 0.24 (0.07 to 0.88), and 0.45 (0.31 to 0.66), 
respectively. bPredicted mortality rates, based on Simplified Acute Physiology Score II at ICU admission, were 39%, 39%, 35%, and 41% in the 
four groups, respectively. ESBL, extended-spectrum β-lactamase; ICU, intensive care unit; MDR, multidrug-resistant; NA, not applicable.Critical Care    Vol 12 No 3    Nseir et al.
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scribe appropriate antibiotic therapy in patients with VAP [43].
Furthermore, the results of our study were not evaluated by an
independent committee to account for the absence of blind-
ing. However, ICU mortality was significantly different between
the two groups. This outcome does not need to be assessed
by a committee blinded to patient assignment. Third, the
number of patients screened for this study could not be pro-
vided and the number of included patients was lower than ini-
tially expected. Potential reasons for this slow recruitment
include strict inclusion and exclusion criteria and difficulties in
differentiating VAT from VAP. Fourth, 21 of 36 (58%) patients
randomly assigned to the no antibiotic group had received
antibiotics during the 8 days following random assignment,
including 15 patients (41%) for subsequent VAP and 6
patients (16%) for infections other than VAT or subsequent
VAP. However, subsequent VAP was a secondary endpoint. In
addition, to adjust for this confounding factor, we have per-
formed a modified ITT analysis excluding those patients ran-
domly assigned to the no antibiotic group but who received
antibiotics for infections other than VAT or subsequent VAP.
Fifth, a computed tomography scan was not systematically
performed to search for nosocomial sinusitis. In addition, no
information could be provided on hospital mortality, oral care,
and type of nutrition. Finally, because of the small sample size,
a type I error could not be excluded. However, the significant
difference found in ICU mortality is probably related to the sig-
nificant difference in subsequent VAP rates between the two
groups.
Conclusion
We conclude that, in patients with VAT, antimicrobial treat-
ment is associated with a greater number of days free of
mechanical ventilation and lower rates of VAP and ICU mortal-
ity. However, antibiotic treatment has no significant impact on
the total duration of mechanical ventilation or ICU stay.
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